他克莫司和雷帕鸣同时吃可以吗

Is it okay to take tacrolimus and tacrolimus at the same time? Tacrolimus, also known as FK506, is a fermentation product isolated from streptomyces tsukubaensis. Its chemical structure belongs to the 23$ macrolide antibiotics. It is a powerful new immunosuppressant that mainly inhibits the release of interleukin-2 (IL-2) and comprehensively inhibits the effect of T lymphocytes. It is 100 times stronger than cyclosporine (CsA). In recent years, as a first-line drug for liver and kidney transplantation, it has been launched in 14 countries including Japan and the United States. Clinical experiments have shown that it has good efficacy in heart, lung, intestinal, bone marrow and other transplants. At the same time, FK506 also plays an active role in the treatment of autoimmune diseases such as atopic dermatitis (AD), systemic lupus erythematosus (SLE), and autoimmune eye diseases.

At the molecular level, tacrolimus apparently functions by binding to a cellular protein (FKBP12) and accumulating within cells to produce its effects. The FKBP12-tacrolimus complex specifically binds and inhibits calcinurin, which inhibits the calcium-dependent signaling pathway in T cells, thereby preventing the transcription of discontinuous lymphokine genes. This drug is a highly immunosuppressive drug, and its activity has been confirmed in vitro and in vivo experiments. This drug inhibits the production of cytotoxic lymphocytes, which are responsible for the main effects of transplant rejection. This drug inhibits the activation of T cells and the proliferation of T helper cells dependent on B cells. It also inhibits the production of lymphokines such as interleukin-2, interleukin-3 and gamma-interferon and the expression of interleukin-2 receptors. At the molecular level, the drug's effects appear to be caused by binding to a cellular protein (FKBP), which also causes the compound to accumulate between cells. In in vivo trials, the drug was found to be effective against liver and kidney transplants.

Typically, tacrolimus has similar immunosuppressive properties to the commonly used drug cyclosporine, but it is more potent at the same dose. Suppressing the immune response using this drug may reduce transplant rejection better than cyclosporine. Clinical trials have confirmed that liver transplant patients who take tacrolimus feel better in the first year after transplant than those who take cyclosporine. The initial dose is 0.15 to 0.2 mg per kilogram of body weight as a daily injection.

The main component of rapamycin is sirolimus, formerly known as rapamycin, which is a new type of powerful lipophilic triene nitrogen-containing macrolide antibiotic immunosuppressant. As a third-generation immunosuppressant, its anti-proliferative effect on peripheral blood mononuclear cells is 50-500 times stronger than that of cyclosporine. Due to its low nephrotoxicity, American Home Products Company (AHP) was officially approved by the FDA in September 1999 as an anti-rejection drug for kidney transplantation. At the same time, it has a variety of activities that have attracted the attention of experts in various fields. It has anti-tumor activity alone or/in combination with streptolytic bacteria, has anti-fungal activity, and is a macrolide antibiotic drug with pleiotropic effects on multiple sclerosis.

Can it be used together with tacrolimus? It also depends on the patient's own condition and the medication should be taken according to the doctor's prescription, and should not be used without permission to avoid serious drug reactions.